Health Trials

Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer

ConditionColorectal Liver Metastasis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTechnische Universität Dresden

About this trial

the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).

Eligibility criteria

Qualifiers

Colorectal cancer with RAS mutation (KRAS or NRAS)

Colorectal liver metastases (single or multiple)

Planned R0 resection of liver metastases (and primary tumor, if present)

Anatomical and non-anatomical liver resection technically feasible

Disqualifiers

Extrahepatic metastases

Planned staged liver resection (e.g. two-stage hepatectomy)

Diagnosis of another cancer < 5 years prior to randomization Exceptions: curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer

Expected lack of compliance

Trial design

Treatments tested in this trial

  • Resection of colorectal liver metastases

Treatment groups

240 Participants
are divided into 2 treatment groups

Locations

37
Department of Surgery at the University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University68167, MannheimBaden-Wurttemberg, Germany
Department of Gastrointestinal-, Thoracic and Vascular Surgery University Hospital Carl Gustav Carus Technische Universität Dresden01307, DresdenSaxony, Germany
Intestinal Center West Middle Franconia, ANregiomed Clinic Ansbach Ansbach Germany
Clinic for General, Vizeral and Transplant Surgery, Augsburg University Hospital Augsburg Germany

Sponsors and collaborators

Technische Universität Dresden

Lead sponsor

German Cancer Research Center

Collaborator

Source ClinicalTrials.gov